Intas Biopharma in talks with Japanese co for outlicensing
Intas Biopharmaceutical Ltd , a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd , would soon enter into an out-licensing and supply deal with a major Japanese pharmaceutical company for its bio-similar drugs. This would be the second such major deal for the Intas Group, after its recent deal with AstraZeneca.
"Intas Biopharma is in talks with a major Japanese company for out-licensing and supply deal of its two bio-similar drugs" said Dr Subir Basak, CEO, Celestial Biologicals Ltd, an associate company of Intas Biopharma. Dr Basak was talking to ET at a conference BIO India 2010, held in Hyderabad last week.
Earlier this month, Intas Pharmaceutical entered into an out-licensing and supply agreement with UK-based drug maker AstraZeneca. As per the deal, Intas Pharma will supply generic, high-end oncological products. Intas Pharmaceutical, the flagship company of the group, is also planning to come out with an IPO early next year.
According to him, the deal would be for two biosimilar drugs – rHu G-CSF (Neukine) and Peg rHu G-CSF (Neupeg). Neukine, a granulocyte colony stimulating factor (G-CSF) was the first recombinant DNA molecule launched by Intas Biopharma in the domestic market in 2004. Neukine, is an injection that promotes growth of white blood cells, which help to fight infections after chemotherapy.
Neupeg is used for treatment of neutropenia (a side effect of cancer chemotherapy). The bio-similar drug, Neukine is jointly developed by Intas Biopharma and European drug major Kwizda Pharma GmbH.
"The talks are on and may take another two months to materialise" Mr Basak said add. Addressing the selective biotech industry audience at the Biotech conference in Hyderabad, he said that his company which has already partners in the US and Australia, wants to spread it wings to other parts of the globe through partnerships. "Now, we are keen to seek more partners outside India for marketing partnership," he said adding that the company is looking at leveraging its product in global market. He further added that Japanese market is one of such attractive markets and hopefully his company would soon make its way into the Japanese market.
Intas Biopharma has three generic versions of the top 10 blockbusters in its product basket. Neukine, Erykine, Intalfa and Neupeg are a few names of bio-similar drugs launched by the company in the domestic and international markets. Intas Biopharma has three subsidiaries, Indus Biotherapeutics Ltd, California-based Biologics Process Development Inc. and Celestial Biologicals Ltd. Kotak Private Equity Group invested $10 million in the company in late 2007 and recently Tata Capital invested in Intas Biopharma.
Oct 11, 2010